{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:26:17Z","timestamp":1790400377231,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"American Regent"},{"name":"Eli-Lilly"},{"name":"Genetech"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer-Ingelheim"},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with inflammatory bowel disease (IBD) may be at higher risk for complications from radiation treatment for prostate cancer. However, available data are limited, and controversy remains regarding the best treatment approach for IBD patients who develop prostate cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study across 4 Department of Veterans Affairs hospital systems. Patients with established IBD who were diagnosed and treated for prostate cancer between 1996\u20132015 were included. We assessed for flares of IBD, IBD-related hospitalizations, and IBD-related surgeries within 6, 12, and 24 months of cancer diagnosis and survival at 1, 2, and 5 years. Flares of IBD were those documented as such by the treating physician, and treatment changed accordingly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred patients with IBD and prostate cancer were identified. Forty-seven were treated with either treatment with external beam radiation or brachytherapy, and 53 were treated with nonradiation modalities. Comparing cohorts with or without radiation treatment, there were no differences in baseline IBD characteristics, Charlson comorbidity index, or prostate cancer stage. Inflammatory bowel disease flares were 2-fold higher for radiation-treated patients within 6 months (10.6% vs 5.7%) and 6\u201312 months (4.3% vs 1.9%) after cancer diagnosis. On multiple logistic regression analysis, radiation treatment (adjusted odds ratio, 4.82; 95% confidence interval, 1.15\u201320.26) was a significant predictor of flares. However, rates of IBD-related hospitalizations or surgeries were not significantly different.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this retrospective, multicenter study, 2-fold higher rates of flare were found within the first year after prostate cancer diagnosis for patients treated with radiation, but there were no differences in IBD-related hospitalizations or surgeries. Although patients should be counseled of these risks, avoidance of radiation therapy in IBD patients with prostate cancer is likely not necessary.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izz175","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T15:59:52Z","timestamp":1565971192000},"page":"728-733","source":"Crossref","is-referenced-by-count":22,"title":["Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy"],"prefix":"10.1093","volume":"26","author":[{"given":"Linda A","family":"Feagins","sequence":"first","affiliation":[{"name":"VA North Texas Health Care System, Dallas, Texas, USA"},{"name":"The University of Texas at Austin, Dell Medical School, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyun","family":"Kim","sequence":"first","affiliation":[{"name":"VA North Texas Health Care System, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalia","family":"Chandrakumaran","sequence":"first","affiliation":[{"name":"McGuire VA Medical Center and Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Gandle","sequence":"first","affiliation":[{"name":"Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina H","family":"Naik","sequence":"first","affiliation":[{"name":"George Washington University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisha J","family":"Cipher","sequence":"first","affiliation":[{"name":"The College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K","family":"Hou","sequence":"first","affiliation":[{"name":"McGuire VA Medical Center and Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Yao","sequence":"first","affiliation":[{"name":"Washington DC VA Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill K J","family":"Gaidos","sequence":"first","affiliation":[{"name":"McGuire VA Medical Center and Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"2020041111452502200_CIT0001","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA."},{"key":"2020041111452502200_CIT0002","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med."},{"key":"2020041111452502200_CIT0003","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med."},{"key":"2020041111452502200_CIT0004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol."},{"key":"2020041111452502200_CIT0005","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer."},{"key":"2020041111452502200_CIT0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med."},{"key":"2020041111452502200_CIT0007","doi-asserted-by":"crossref","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2013","edition":"3"},{"key":"2020041111452502200_CIT0008","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","article-title":"Patient and treatment factors associated with complications after prostate brachytherapy","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol."},{"key":"2020041111452502200_CIT0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0360-3016(97)00583-X","article-title":"Prostate brachytherapy in patients with inflammatory bowel disease","volume":"40","author":"Grann","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2020041111452502200_CIT0010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0360-3016(99)00374-0","article-title":"Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms","volume":"46","author":"Willett","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2020041111452502200_CIT0011","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brachy.2012.04.008","article-title":"Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease","volume":"12","author":"Pai","year":"2013","journal-title":"Brachytherapy."},{"key":"2020041111452502200_CIT0012","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/COC.0000000000000010","article-title":"Low toxicity in inflammatory bowel disease patients treated with abdominal and pelvic radiation therapy","volume":"38","author":"White","year":"2015","journal-title":"Am J Clin Oncol."},{"key":"2020041111452502200_CIT0013","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.rpor.2016.10.005","article-title":"Long term clinical toxicity of radiation therapy in prostate cancer patients with inflammatory bowel disease","volume":"22","author":"Gestaut","year":"2017","journal-title":"Rep Pract Oncol Radiother."},{"key":"2020041111452502200_CIT0014","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2017.01.030","article-title":"Implications of prostate cancer treatment in men with inflammatory bowel disease","volume":"104","author":"Kirk","year":"2017","journal-title":"Urology."},{"key":"2020041111452502200_CIT0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: a call for action","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2020041111452502200_CIT0016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.radonc.2019.03.006","article-title":"Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): an international systematic review and meta-analysis","volume":"135","author":"Lin","year":"2019","journal-title":"Radiother Oncol."},{"key":"2020041111452502200_CIT0017","first-page":"CD012529","article-title":"Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers","volume":"1","author":"Lawrie","year":"2018","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/5\/728\/33035357\/izz175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/5\/728\/33035357\/izz175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T15:45:38Z","timestamp":1586619938000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/5\/728\/5550115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,8,14]]},"published-print":{"date-parts":[[2020,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz175","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,8,14]]}}}